- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 rS - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1, Normal saline solution (NSS), Placebo - Phase 1, Normal saline solution (NSS), Placebo - Phase 2, SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1, Normal saline solution (NSS), Placebo, Day 21 - Phase 1, SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 2
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 1,419 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Meridian, Idaho • Newton, Kansas + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
- Conditions
- Influenza
- Interventions
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3, Quadrivalent RIV with H3 strain 4, Quadrivalent RIV with 2018-2019 NH H3 strain
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • Rochester, New York • North Charleston, South Carolina
- Conditions
- Influenza
- Interventions
- Influenza Vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Influenza, Healthy Volunteers
- Interventions
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more
- Conditions
- Hepatitis B
- Interventions
- HEPLISAV
- Biological
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 11 Years to 55 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Boardman, Ohio • Grove City, Pennsylvania • Pittsburgh, Pennsylvania + 3 more
- Conditions
- AIDS, HIV
- Interventions
- Fluarix, Pneumovax, Placebo
- Biological · Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Influenza
- Interventions
- VAX161 [STF2.HA5 H5N1]
- Biological
- Lead sponsor
- VaxInnate Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 224 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Miami, Florida • Lenexa, Kansas
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Interventions
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine, Pneumococcal Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New York, New York
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- G17DT Immunogen, cisplatin, fluorouracil
- Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2002
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Influenza
- Interventions
- Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
- Conditions
- Influenza
- Interventions
- Fluzone® (intramuscular), FluMist® (intranasal)
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 8 Years to 100 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Pneumococcal Infections
- Interventions
- V114, Prevnar 13™, PNEUMOVAX™23
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Shigellosis
- Interventions
- Flexyn2a, Placebo, Flexyn2a plus adjuvant
- Biological
- Lead sponsor
- LimmaTech Biologics AG
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Silver Spring, Maryland
- Conditions
- HIV Infections, HIV Seronegativity
- Interventions
- ALVAC-HIV MN120TMG (vCP205)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2001
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
- Conditions
- Staphylococcal Infections
- Interventions
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo
- Biological · Procedure
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 456 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more
- Conditions
- Influenza
- Interventions
- Quadrivalent inactivated influenza vaccine (IIV)
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 2 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Influenza, Human
- Interventions
- bioCSL Trivalent Influenza Virus Vaccine (CSL TIV), Comparator Quadrivalent Influenza Virus Vaccine
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 5 Years to 8 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Boise, Idaho • St Louis, Missouri + 8 more
- Conditions
- Cocaine Dependence
- Interventions
- TA-CD Vaccination, Placebo Injection
- Drug · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • New York, New York • Cincinnati, Ohio + 2 more
- Conditions
- Healthy Volunteers, Influenza
- Interventions
- Flu H5 egg pandemic low dose vaccine, with adjuvant, Flu H5 Egg Pandemic medium dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, with adjuvant, Flu H5 Egg Pandemic high dose vaccine, without adjuvant
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 640 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 16
- States / cities
- Tempe, Arizona • Rolling Hills Estates, California • San Diego, California + 12 more
- Conditions
- Meningitis, Meningococcal Meningitis, Meningococcal Infections
- Interventions
- Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed, GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 1,715 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Downey, California + 28 more
- Conditions
- Influenza Immunization
- Interventions
- Pandemic flu H5 mRNA vaccine, Placebo
- Biological · Other
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 14
- States / cities
- La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more
- Conditions
- Rabies
- Interventions
- Purified Vero Rabies Vaccine (VRVg) - Serum Free, Imovax® Rabies: inactivated rabies vaccine
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 6
- States / cities
- Redding, California • Sacramento, California • Omaha, Nebraska + 3 more
- Conditions
- Influenza
- Interventions
- Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative, Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation, Fluzone High-Dose vaccine, 2015-2016 formulation
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more